666 related articles for article (PubMed ID: 19544328)
1. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
[TBL] [Abstract][Full Text] [Related]
2. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Kojima Y; Sasaki S; Shinoura H; Hayase M; Kubota Y; Hayashi Y; Tsujimoto G; Kohri K
Prostate; 2007 Sep; 67(12):1285-92. PubMed ID: 17626248
[TBL] [Abstract][Full Text] [Related]
3. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
[TBL] [Abstract][Full Text] [Related]
4. Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients.
Kojima Y; Sasaki S; Shinoura H; Hayashi Y; Tsujimoto G; Kohri K
Prostate; 2006 May; 66(7):761-7. PubMed ID: 16425183
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
6. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of α1a and α1d-adrenoceptors in the prostate by administration of subtype selective α1-adrenoceptor antagonist tamsulosin in patients with benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Imura M; Oda N; Kiniwa M; Hayashi Y; Kohri K
J Urol; 2011 Oct; 186(4):1530-6. PubMed ID: 21855934
[TBL] [Abstract][Full Text] [Related]
8. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
9. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
10. [The role of alpha1-adrenoceptor subtypes in benign prostatic hyperplasia-from bed to bench].
Kojima Y; Hayase M; Imura M; Okada S; Kubota Y; Sasaki S; Hayashi Y; Kohri K
Hinyokika Kiyo; 2008 Jun; 54(6):457-62. PubMed ID: 18634446
[TBL] [Abstract][Full Text] [Related]
11. Doxazosin treatment causes differential alterations of alpha 1-adrenoceptor subtypes in the rat kidney, heart and aorta.
Yono M; Foster HE; Shin D; Takahashi W; Pouresmail M; Latifpour J
Life Sci; 2004 Oct; 75(21):2605-14. PubMed ID: 15363664
[TBL] [Abstract][Full Text] [Related]
12. An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists.
Pulito VL; Li X; Varga SS; Mulcahy LS; Clark KS; Halbert SA; Reitz AB; Murray WV; Jolliffe LK
J Pharmacol Exp Ther; 2000 Jul; 294(1):224-9. PubMed ID: 10871316
[TBL] [Abstract][Full Text] [Related]
13. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
[TBL] [Abstract][Full Text] [Related]
14. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice.
Marinese D; Patel R; Walden PD
Prostate; 2003 Feb; 54(3):230-7. PubMed ID: 12518328
[TBL] [Abstract][Full Text] [Related]
16. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
[TBL] [Abstract][Full Text] [Related]
17. RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia.
Nanda K; Naruganahalli KS; Gupta S; Malhotra S; Tiwari A; Hegde LG; Jain S; Sinha N; Gupta JB; Chugh A; Anand N; Ray A
Eur J Pharmacol; 2009 Apr; 607(1-3):213-9. PubMed ID: 19239913
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].
Ikegaki I
Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):63-9. PubMed ID: 10976457
[TBL] [Abstract][Full Text] [Related]
19. [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
Akasaka T; Funaki H; Hirano S; Ohinata M; Fujishima M; Kudou T; Suzuki A; Iinuma M
Hinyokika Kiyo; 2003 Apr; 49(4):189-93. PubMed ID: 12784711
[TBL] [Abstract][Full Text] [Related]
20. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
